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Protein kinases exist in inactive and active states, but
little attention has been paid to which state is or
should be the target in drug discovery efforts. In this
issue of Chemistry & Biology, Okram et al. [1] tackle
this issue and show that inhibitors can be designed
specifically to bind to inactive Abl.
Over 500 protein kinases comprising approximately 2%
of the human genome have been identified; however,
a limited number are well characterized functionally
and structurally [2]. Kinases’ abilities to activate or inac-
tivate other proteins (including sometimes themselves)
by phosphorylation make them key controllers in vari-
ous cellular processes such as cell growth, differentia-
tion, metabolism, and apoptosis. Deregulation of kinase
activities is well associated with a multitude of disease
states, particularly cancer in which excessive kinase ac-
tivity is associated with cellular transformation. The ki-
nase family thus provides a treasure trove of therapeutic
targets, second only to G protein-coupled receptors [3].
The basis for therapeutic intervention is through chemi-
cal inhibition of kinase activity.
A major issue with respect to protein kinases as thera-
peutic targets has been the lack of selectivity of ATP-
competitive inhibitors toward their targets. Since the
ATP binding pocket is homologous in the majority of pro-
tein kinases, it is highly probable that an ATP-directed
small molecule will bind to a number of targets albeit
with varying degrees of potency. The observation that
ATP [4] and small molecule ATP antagonists [5] can
bind with different affinities to active and inactive kinases
raises the possibility of designing inhibitors specific for
inactive confirmations resulting in higher ligand selectiv-
ity. Conventional ‘‘type I’’ inhibitors bind to the ATP cleft
in an open (DFG in) active conformation (Figure 1) and
this conformation is generally similar in most kinases
[6]. In contrast, the ATP binding site of the inactive con-
formation (DFG out) is more unique, and ligand design
based on this scaffold results in ‘‘type II’’ molecules
that are not readily accommodated in binding sites of
active kinases, illustrated for Abl in Figure 1.
The fact that kinases exist in active and/or inactive
states in cells has been known for more than 20 years
[7]. The activation of protein kinases occurs mainly
through conformational adjustments induced by post-
translational modification (principally phosphorylation)
and, in some cases, by binding of a regulatory subunit.
Only recently have differences between active and inac-
tive kinases been considered in drug discovery and
thought given to how this could be exploited in the de-
sign of specific inhibitors of ATP binding [1, 8, 9]. An ex-
ample of this is the binding of cyclins to CDKs, an event
triggering a large shift in the position of the activation
loop and subsequent alignment of the residues com-
prising the catalytic domain. Conformational mobility
of the loop regions can be exploited in structure-baseddesign, and recently has resulted in serendipitous dis-
coveries of ligands that either sequestered unique con-
formations that are incompatible with ATP binding [10],
or utilized a novel allosteric binding site [11].
Despite these new developments in targeting inactive
kinase conformations, the majority of efforts in drug dis-
covery do not consider the kinase activation state. In
some instances, studies present activity data for potent
inhibitors of a kinase, obviously determined in an assay
using the active enzyme, but, surprisingly, designed or
explained using X-ray crystal structures of the inactive
form. This is particularly common for CDK2 inhibitor dis-
covery where the significant structural changes occur-
ring upon activation of the kinase can result in dramatic
differences in inhibitor binding [12, 13].
The first attempt to quantify the differences in ligand
binding between active and inactive kinases by Davis
et al. [14] raised some concerns. Although the authors
suggested that differences do exist with implications
for drug design, the observation was made that the in-
hibitor studied bound with an overall similar mode to
the active and inactive forms. More substantial proof
that activation changes result in significant differences
in ligand binding with direct implications for drug design
emerged recently [9]. A series of CDK2 inhibitors studied
in monomeric (inactive) and cyclin bound (active) forms
demonstrated that small changes in the ATP binding site
could have a profound effect on ligand binding.
The present study from Okram et al. [1] provides the
first description of the inhibitor determinants required
for binding and stabilizing inactive kinase conformations
(type II inhibitors), and demonstrates how these can be
used in the design of a new generation of ligands. The
principle strategy reported for the design of type II kinase
ligands is to append appropriate pharmacophoric ele-
ments to type I ligands, thereby transforming them into
compounds that preferentially interact with inactive ki-
nases, targeting Abl as a proof of principle. In this work,
several type I progenitors were modified through attach-
ment of urea and benzamide groups and screened
against a kinase panel [1]. Selective targeting of inactive
kinase structures by these compounds was confirmed
through assay results demonstrating that unphosphory-
lated Abl (inactive) was preferentially inhibited by type II
inhibitors in contrast to the effects of type I inhibitors and
in addition, a crystal structure of the complex between
a type II molecule and c-Abl showed that a similar confor-
mation to Gleevec (known to bind to inactive conforma-
tion) was obtained. A major observation is that type II in-
hibitors themselves can induce structural changes and
result in an inactive conformation [5]. Activity data dem-
onstrated that the type II compounds also can bind to the
phosphorylated active Abl, thus implying that they can
drag the protein from an active to an inactive conforma-
tion. This conclusion, however, requires further investiga-
tion since no direct comparison has been made of the
same ligand/kinase complex in both the phosphorylated
and unphosphorylated forms. For this case, it could be
possible for the ligand either to induce the protein confor-
mation [5] or to bind to a transitional activation state [15].
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694Figure 1. Inhibition of Active and Inactive
Conformations of Abl
(A) Inactive Abl (I, green) transforms to the ac-
tive (A, blue) form after an activation event
(phosphorylation). The conformational alter-
ations occurring upon activation adjust the
activation loop (magenta), converting the
ATP binding pocket to an open conformation
where it can accommodate ATP and sub-
strate. As the ATP binding pockets of active
kinases (A) in general are homologous, it is
highly probable that any small molecule de-
sign guided by an active kinase will bind to
a number of other active kinases resulting in
poor selectivity (type I). The ATP binding
site of (I) has distinct differences from that
of (A) and, in general, from other kinases
and thus can be exploited to design type II in-
hibitors (L) that do not bind to (A), and are
more selective for (I).
(B) A selective inhibitor (L), which cannot be
accommodated in the binding site of (A),
may drive the equilibrium to the predomi-
nantly (I) conformation, thereby resulting in
less active protein available for biological
processes.
PDB codes 1IEP and 1M52[5] were used for
the above figure.In this current study, convincing evidence is presented
for the design of specific and selective inactive-confor-
mation inhibitors of Abl and other protein kinases. The
surprising results were that the type II compounds
showed broader selectivity profiles compared to the
type I inhibitors in addition to gaining potency. Based
on these results, it is conceivable that the development
of the next generation of specific and selective kinase
drugs will be accelerated. This approach, however, will
be dependent on the availability of more structural infor-
mation for many of the kinases that remain uncharacter-
ized. The authors correctly state that much more needs
to be learned, but these results will provide a foundation
on which to generate further knowledge of the determi-
nants of type II inhibitors and thus will enable other ki-
nases or other proteins families sharing similar features
(i.e., activation, phosphorylation) to be inhibited in this
way. We are coming to a stage where we can go beyond
specific inhibition of a particular protein to inhibiting
a specific conformation of that protein. This advance
will lead to new tools to study the in vivo effects of con-
former-specific inhibition and enable the impact of this
on the dynamics of proteins in solution to be assessed.
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